Bai X L, Jia L, Liang T B
Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine; Clinical Medical Research Center for Hepatobiliary Pancreatic Diseases of Zhejiang Province, Hangzhou 310000, China.
Zhonghua Wai Ke Za Zhi. 2020 Oct 1;58(10):741-744. doi: 10.3760/cma.j.cn112139-20200620-00475.
The low surgical resection rate and high postoperative recurrence rate of hepatocellular carcinoma(HCC) are urgent clinical problems to be solved. Therefore, it is important to develop effective perioperative treatment. In recent years, a growing number of studies have shown that systemic therapy is expected to break through the limitations of traditional local treatment and play an important role in preoperative treatment. For example, some novel targeted agents and immunocheckpoint inhibitors have shown excellent potential as neoadjuvant treatment for HCC. Meanwhile, researchers have explored the application of systemic therapy as adjuvant therapy, but due to different criteria for patient selection, no consensus is reached on its efficacy. By far, there is no standard procedure for the application of systemic therapy in HCC perioperative period, little is known about the efficacy and safety of targeted drugs and immunotherapy. This article discusses the feasibility of systemic therapy as neoadjuvant and adjuvant treatment of HCC, as well as its adverse events, with an aim to provide new horizons of HCC systemic therapy in the perioperative period.
肝细胞癌（HCC）手术切除率低、术后复发率高是亟待解决的临床问题。因此，开展有效的围手术期治疗具有重要意义。近年来，越来越多的研究表明，全身治疗有望突破传统局部治疗的局限，在术前治疗中发挥重要作用。例如，一些新型靶向药物和免疫检查点抑制剂作为HCC新辅助治疗已显示出优异的潜力。同时，研究人员也在探索全身治疗作为辅助治疗的应用，但由于患者选择标准不同，其疗效尚未达成共识。迄今为止，HCC围手术期全身治疗尚无标准流程，对靶向药物和免疫治疗的疗效及安全性了解甚少。本文探讨全身治疗作为HCC新辅助和辅助治疗的可行性及其不良事件，旨在为HCC围手术期全身治疗提供新视野。
